Likelihood of Approval and Phase Transition Success Rate Model – Crizotinib in Metastatic Transitional (Urothelial) Tract Cancer
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Crizotinib in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Crizotinib in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:
Crizotinib (Xalkori, Crizalk) is a pyrazolylpyridine derivative acts as anti-cancer agent. It is formulated as hard gelatin capsules, pellets for oral route of administration. Xalkori is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that is advanced or has spread to other parts of the body and is caused by a defect in a gene called ALK (anaplastic lymphoma kinase). It is also indicated for the treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Xalkori is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Xalkori also indictaed as first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Xalkori is indicated to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and as a monotherapy in the treatment of patients with ROS1-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). Xalkori is indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive and indication for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. The drug candidate is under development for treatment of malignant neoplasms, advanced malignancies including anaplastic large cell lymphoma (ALCL), uveal melanoma, metastatic and pediatric colorectal cancer, metastatic breast cancer, gastric cancer, cholangiocarcinoma, metastatic ovarian cancer, metastatic papillary renal cell carcinoma, hepatocellular carcinoma (hepatic carcinoma), refractory multiple myeloma, neuroblastoma, rhabdomyosarcoma, clear cell sarcoma, anaplastic thyroid cancer, metastatic urothelial cancer, metastatic castration-resistant prostate cancer, HER2 negative breast cancer, triple negative breast cancer and glioblastoma multiforme as first and second line of therapy. It can administered through oral route as capsules and tablets.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Crizotinib LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports